Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Media
Press Releases - 2003
Newron inaugurate their new premises and laboratories21/11/2003 | 
ENG
| ||
Newron's safinamide is well tolerated without significant drug to drug interaction in an open study in uncontrolled seizure patients18/11/2003 |
ENG
| ||
Newron receives US IND approval for safinamide in Parkinson's Disease23/07/2003 |
ENG
| 
ITA
| |
Newron's Ralfinamide is well tolerated and shows oral bioavailability in phase 1 trials16/06/2003 |
ENG
|
ITA
| |
Newron Pharmaceuticals publishes promising data on novel theraphy for pain04/03/2003 |
ENG
|
ITA
| |
Newron Releases Positive Preliminary Phase II Data For Safinamide in Parkinson's Disease09/01/2003 |
ENG
|